Evidence map›Paper›PMID 36209416›Full record

ArticleChemical research in toxicology2022

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox.

Dieter Lang, Simone I Schulz, Isabel Piel, Dieudonné T Tshitenge, Heino Stass

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Chemical research in toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Current drug metabolism · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dieter LangDrug Metabolism and Pharmacokinetics, Bayer AG, 42096 Wuppertal, Germany.ORCID 0000-0002-2968-638X
Simone I SchulzBayer AG, 42096 Wuppertal, Germany.
Isabel PielBayer AG, 42096 Wuppertal, Germany.
Dieudonné T TshitengeBayer AG, 42096 Wuppertal, Germany.
Heino StassBayer AG, 42096 Wuppertal, Germany.
Bayer (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oral antiparasitic drug nifurtimox has been used to treat Chagas disease for more than 50 years. Historical studies determined that very little nifurtimox is excreted unchanged, but contemporaneous preclinical studies of radiolabeled nifurtimox found almost all of the radiolabel was rapidly excreted, suggesting that metabolism is extensive. Attempts to study nifurtimox metabolism have had limited success, yet this knowledge is fundamental to characterizing the pharmacokinetics and pharmacodynamics of the drug. We conducted

Indexed as

Body FluidsTandem Mass SpectrometryAnimalsChromatography, High Pressure LiquidFecesHumansNifurtimoxRatsNifurtimox

Identifiers

PMID36209416
PMCPMC9682525
OpenAlexW4303858857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.